Sanofi's Shock Therapy Enrages the French

Cita: 

Torsoli, Albertina [2012], “Sanofi's Shock Therapy Enrages the French”, Business Week, New York, 9 de agosto, http://www.bloomberg.com/bw/articles/2012-08-09/sanofis-shock-therapy-en...

Fuente: 
Business Week
Fecha de publicación: 
Jueves, Agosto 9, 2012
Idea principal: 

Among the major French companies that have triggered protests at home this summer by announcing job cuts, Sanofi stands out for its audacity. France's biggest drugmaker plans to slash its research and development staff in Toulouse and Montpellier and is shifting its focus across the Atlantic to Cambridge, MA. CEO Chris Viehbacher says he hopes some of Genzyme's innovative culture will rub off on Sanofi and help both companies develop drugs. Sanofi's profitable drugs, such as the blood thinner Plavix, are losing ground to generic medicines. To change that, Viehbacher reorganized Sanofi scientists into more flexible teams, drawing from Genzyme's experience. French politicians and labor leaders aren't thrilled.